Clinical Trials Browser

Active not recruiting × INDUSTRY × Radiotherapy × Clear all

Prostatic Neoplasms

NCT03491683 2026-03-19

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Phase 1/2 Active not recruiting

52 enrolled

CNS

Glioblastoma

NCT05109728 2026-03-16

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Phase 1 Active not recruiting

65 enrolled

CNS

Glioblastoma

NCT03407144 2026-02-19

MK-3475-667

Phase 2 Active not recruiting

340 enrolled

Lymphoid

Hodgkin Disease

NCT05009069 2026-01-22

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

58 enrolled

Gastrointestinal

Rectal Neoplasms

NCT07192588 2025-09-25

GuARD

Phase 2 Active not recruiting

273 enrolled

Breast

Breast Neoplasms, Radiodermatitis

NCT03725059 2025-07-11

KEYNOTE-756

Phase 3 Active not recruiting

1,240 enrolled

Breast

Breast Neoplasms

NCT04121455 2025-06-25

GLORIA

Phase 1/2 Active not recruiting

117 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Phase 1 Active not recruiting

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT04210115 2024-11-15

KEYNOTE 975

Phase 3 Active not recruiting

703 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Clinical Trials

PRIMORDIUM

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

MK-3475-667

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

GuARD

KEYNOTE-756

GLORIA

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

KEYNOTE 975